Drug Trial Radar · NCT02940860
Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease
Last checked: Nov 20, 2026Latest source record: Oct 6, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,538
Actual
Start
Nov 29, 2016
Primary completion
May 29, 2018
Study completion May 29, 2018
Sponsor
- Lead sponsor
- Pharmacosmos A/SIndustry
- Sponsor type
- Industry
- First posted
- Oct 21, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluation of safety and efficacy of iron isomaltoside/ferric derisomaltose compared with iron sucrose, in subjects with both non-dialysis-dependent chronic kidney disease (NDD-CKD) and iron deficiency anaemia (IDA).
Conditions
- Iron Deficiency Anaemia
- Iron Deficiency Anemia
- Chronic Kidney Disease
Interventions
Iron isomaltoside/ferric derisomaltoseDrug
Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial. The dose of iron isomaltoside/ferric derisomaltose for the individual subject was set to 1000 mg. The dose was diluted in 100 mL 0.9 % sodium chloride (100 mL bags) and administered as a single IV infusion over approximately 20 minutes.
Iron sucroseDrug
Iron sucrose (Venofer®; 20 mg elemental iron/mL) was the comparator in this trial. Iron sucrose was administered as 200 mg undiluted IV injections over approximately 2-5 minutes and repeated according to standard practice or physician choice up to a maximum of five times within the first two weeks starting at baseline. A cumulative dose of 1000 mg was recommended.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Hemoglobin (Hb) From Baseline to Week 8Time frame: Baseline to week 8
- Incidence of Protocol-defined Serious or Severe Hypersensitivity ReactionsTime frame: Baseline to week 8
Locations
141 sites in 1 country. Site status is shown where the registry gives one.
Pharmacosmos Investigational Site
Huntsville, Alabama
Pharmacosmos Investigational Site
Little Rock, Arkansas
Pharmacosmos Investigational Site
Little Rock, Arkansas
Pharmacosmos Investigational Site
Chula Vista, California
Pharmacosmos Investigational Site
Fresno, California
Pharmacosmos Investigational Site
Glendale, California
Pharmacosmos Investigational Site
Glendale, California
Pharmacosmos Investigational Site
Granada Hills, California
Pharmacosmos Investigational Site
La Mesa, California
Pharmacosmos Investigational Site
Los Angeles, California
Pharmacosmos Investigational Site
Los Angeles, California
Pharmacosmos Investigational Site1
Los Angeles, California
Pharmacosmos Investigational Site2
Los Angeles, California
Pharmacosmos Investigational Site
Los Angeles, California
Pharmacosmos Investigational Site
Lynwood, California
Pharmacosmos Investigational Site
Montebello, California
Pharmacosmos Investigational Site
Northridge, California
Pharmacosmos Investigational Site
Northridge, California
Pharmacosmos Investigational Site
Porterville, California
Pharmacosmos Investigational Site
Rialto, California
Pharmacosmos Investigational Site
Riverside, California
Pharmacosmos Investigational Site
Sacramento, California
Pharmacosmos Investigational Site
San Dimas, California
Pharmacosmos Investigational Site
San Francisco, California
Pharmacosmos Investigational Site
Tarzana, California
Pharmacosmos Investigational Site
Arvada, Colorado
Pharmacosmos Investigational Site
Denver, Colorado
Pharmacosmos Investigational Site
Westminster, Colorado
Pharmacosmos Investigational Site
Middlebury, Connecticut
Pharmacosmos Investigational Site
Plainville, Connecticut
Pharmacosmos Investigational Site
Boynton Beach, Florida
Pharmacosmos Investigational Site
Brandon, Florida
Pharmacosmos Investigational Site
Coral Gables, Florida
Pharmacosmos Investigational Site
Coral Springs, Florida
Pharmacosmos Investigational Site
Doral, Florida
Pharmacosmos Investigational Site
Fort Lauderdale, Florida
Pharmacosmos Investigational Site1
Hialeah, Florida
Pharmacosmos Investigational Site2
Hialeah, Florida
Pharmacosmos Investigational Site3
Hialeah, Florida
Pharmacosmos Investigational Site
Hollywood, Florida
Showing 40 of 141 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.